MYC and hepatocellular carcinoma: OTX-2002 is currently undergoing a phase I/II clinical trial in patients with HCC or other solid tumors with c-Myc involvement to determine its antitumoral activity alone or in combination with other treatments such as tyrosine kinase inhibitors (TKI) or ICI (107, 108).